Comparative Pharmacology
Head-to-head clinical analysis: DURLAZA versus INTEGRILIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURLAZA versus INTEGRILIN.
DURLAZA vs INTEGRILIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Durlaza (aspirin) irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting thromboxane A2 synthesis and reducing platelet aggregation.
Reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by preventing fibrinogen binding.
325 mg orally once daily
Acute coronary syndrome: IV bolus of 180 mcg/kg, followed by continuous IV infusion of 2 mcg/kg/min for up to 72 hours. Percutaneous coronary intervention: IV bolus of 180 mcg/kg immediately before PCI, followed by continuous IV infusion of 2 mcg/kg/min for up to 18-24 hours, with a second 180 mcg/kg bolus 10 minutes after the first.
None Documented
None Documented
2-4 hours (prolonged in renal impairment; up to 10-20 hours in severe impairment). Clinical dosing adjustments required when CrCl <30 mL/min.
Terminal elimination half-life: ~2.5 hours (2-3 hours) after intravenous administration; clinical context: rapid clearance allows return of platelet function within 4 hours after infusion cessation.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal. Negligible hepatic metabolism.
Renal: ~50% as unchanged drug and metabolites, Biliary/fecal: minimal; total clearance approximately 55-58% renal.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent